^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Vulvar Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
Published date:
06/29/2021
Excerpt:
A forty-year-old Filipino woman presented to our center with recurrent VCCC...Complete clinical response...and RECISTv1.1 PR on PET-CT scan...was seen after 3 cycles of pembrolizumab...our patient with VCCC harboring a high PD-L1 CPS experienced durable and meaningful response to fifth-line pembrolizumab.
DOI:
https://doi.org/10.2147/OTT.S309661
